| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 25.37 | -0.02 (-0.08%) | 12.75 - 25.67 | 145.6 thousand (Above Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 25.48 |
|---|---|
| Previous Close | 25.39 |
| Day's Range | 25.21 - 25.64 |
| Market Cap | 547.4M |
| Avg Volume (10 Day) | 127.5K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.39 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
AMAG Pharmaceuticals to Present at the Needham Healthcare Conference
Business Wire - Friday 04/26/2013 4:05 PM ET
AMAG Announces First Quarter 2013 Financial Results
Business Wire - Tuesday 04/23/2013 4:05 PM ET
AMAG Pharmaceuticals, Inc. to Host Conference Call on April 23, 2013 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2013
Business Wire - Friday 04/19/2013 4:30 PM ET
| AMAG | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 38.57% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 6.24 |
| Company | Last | Change |
|---|---|---|
| Synta Pharmaceuticals Corp | 7.50 | +0.13% |
| SurModics Inc | 26.41 | +0.19% |
| Trinity Biotech PLC | 16.55 | +0.61% |
| Quidel Corp | 23.04 | +0.96% |
| Accelerate Diagnostics Inc | 7.92 | +0.76% |
Data is delayed by at least 15 min.